TRBV9 and autoimmune disease: We reasoned that the selective deletion of T cells carrying TRBV9+ TCRs using a cytotoxic anti-TRBV9 antibody (Fig. 1b) might provide a safe and effective therapy for HLA-B*27-associated autoimmune diseases.